Letrozole (Femara) has replaced clomid as the recommended first-line ovulation induction agent, particularly for PMOS. The landmark NICHD trial showed letrozole achieves a 27.5% live birth rate vs. 19.1% for clomid, with fewer multiples and no endometrial thinning. Both are affordable ($30–$150/cycle) and well-tolerated.
Key Takeaways
Letrozole achieves 27.5% live birth rate vs clomid's 19.1% in PMOS patients — a significant clinical difference
Letrozole doesn't thin the endometrium or reduce cervical mucus, both common clomid side effects that can work against implantation
ASRM now recommends letrozole as first-line for PMOS-related anovulation, with clomid as a second-line alternative
Clomid still has a role for letrozole non-responders, specific clinical scenarios, and patients without PMOS where the evidence gap is smaller
The Two Most Prescribed Fertility Drugs, Head to Head
If you're starting fertility treatment, there's a good chance your first prescription will be either letrozole (Femara) or clomiphene citrate (Clomid). Both are oral ovulation induction agents that have helped millions of women conceive — but they work differently, and the evidence increasingly favors one over the other.
How They Work: Different Mechanisms, Different Results
Letrozole (Femara)
Letrozole is an aromatase inhibitor — it blocks the enzyme that converts androgens to estrogen. The resulting temporary estrogen drop signals the brain to ramp up FSH production, stimulating follicle growth. Once stopped, estrogen levels normalize quickly, allowing the endometrium to thicken naturally.
Clomiphene Citrate (Clomid/Serophene)
Clomid is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus, tricking the brain into thinking estrogen is low — which triggers increased FSH production. The key difference: clomid's anti-estrogen effects persist throughout the cycle, including at the endometrium and cervix.
💡 Letrozole's key advantage: it doesn't have anti-estrogen effects on the uterine lining. Clomid can thin the endometrium and thicken cervical mucus — both of which work against implantation even when ovulation is successfully induced.
The Evidence: Letrozole Wins
| Outcome | Letrozole | Clomid | Source |
|---|---|---|---|
| Live birth rate (PMOS) | 27.5% | 19.1% | NICHD RCT, NEJM 2014 |
| Ovulation rate (PMOS) | 61.7% | 48.3% | NICHD RCT |
| Multiple pregnancy rate | 3.4% | 7.4% | NICHD RCT |
| Endometrial thickness | 8–10mm average | 6–8mm average | Multiple studies |
| Miscarriage rate | Similar | Similar | No significant difference |
| Birth defect rate | No increase | No increase | Both confirmed safe |
The landmark 2014 NICHD trial (published in NEJM) randomized 750 women with PMOS to letrozole vs clomid. Letrozole produced significantly higher live birth rates (27.5% vs 19.1%), higher ovulation rates, and lower rates of twins. This trial was the primary driver of letrozole becoming the recommended first-line treatment.
Letrozole vs Clomid: Detailed Comparison
| Factor | Letrozole | Clomid |
|---|---|---|
| Typical dose | 2.5–7.5mg, days 3–7 | 50–150mg, days 3–7 or 5–9 |
| Cost per cycle | $30–$100 | $50–$150 |
| Generic available | Yes | Yes |
| Effect on lining | No thinning (pro) | Can thin endometrium (con) |
| Effect on cervical mucus | No adverse effect | Can thicken/reduce (con) |
| Half-life | ~45 hours | ~5–7 days |
| Accumulation | Cleared quickly | Can accumulate over cycles |
| FDA approval for fertility | Off-label (approved for breast cancer) | FDA-approved for ovulation induction |
| ASRM recommendation | First-line for PMOS | Second-line alternative |
| Side effects | Headache, fatigue, hot flashes | Hot flashes, mood changes, visual disturbances, bloating |
Why Clomid Is Still Used
Given the evidence favoring letrozole, why does clomid remain widely prescribed? Several reasons:
- FDA approval: Clomid has FDA approval for ovulation induction; letrozole is technically off-label (approved for breast cancer). Some providers and insurance plans prefer the on-label option.
- Decades of data: Clomid has been used since the 1960s — some providers have deeper comfort with its long track record.
- Letrozole non-responders: A minority of patients respond better to clomid. If letrozole fails to induce ovulation after 2–3 dose escalations, switching to clomid is a reasonable next step.
- Cost and access: In some markets, clomid is more readily available or slightly cheaper.
- Combination protocols: Some REs use clomid + letrozole together, or alternate between cycles.
What to Ask Your Doctor
If your provider prescribes clomid as a first-line treatment for PMOS-related anovulation, it's reasonable to ask about letrozole. Key points for the conversation:
- ASRM guidelines now recommend letrozole as first-line for PMOS
- The NICHD trial showed significantly higher live birth rates with letrozole
- Letrozole has fewer endometrial and cervical mucus side effects
- If there's a specific reason your provider prefers clomid for your case, ask what it is — there may be a valid clinical rationale
💡 For non-PMOS patients (unexplained infertility, mild male factor), the evidence difference between letrozole and clomid is smaller. Your RE may have valid reasons for choosing either drug based on your specific diagnosis and response patterns.
For supplement support alongside ovulation induction medications, visit LifeFertile. For the emotional journey of medicated cycles and the two-week wait, FertileStart has support resources.